PPAR ligands for metabolic disorders

被引：37

作者：

Etgen, GJ ^{[1
]}

Mantlo, N ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Div A, Indianapolis, IN 46285 USA

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2003年 / 3卷 / 14期

关键词：

D O I：

10.2174/1568026033451673

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

As master regulators of lipid metabolism the peroxisome proliferator activated receptor (PPAR) family controls a wide variety of cellular processes, and thus it is not surprising that a large effort has focussed on discovering agents to pharmacologically modulate activity of these receptors. Early generation PPAR ligands, such as the fibrates and the thiazolidinediones (TZDs), were discovered empirically through an in vivo structure activity relationship exercise, whereas currently PPAR ligands are more often identified through target based structural design using cloned and expressed receptors. Regardless of how they were discovered, the development and clinical use of PPAR ligands throughout the last decade has greatly advanced understanding of the physiological function and therapeutic value of modulating these receptors. This review will briefly examine the PPAR family and then outline in greater detail select PPAR ligands indicated for the treatment of metabolic disorders.

引用

页码：1649 / 1661

页数：13

共 79 条

[1] Insulin resistance in type 2 diabetes: role of fatty acids [J].

Arner, P .

DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 :S5-S9

[2] The mechanisms of action of PPARs [J].

Berger, J ;

Moller, DE .

ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435

[3] Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects [J].

Berger, J ;

Leibowitz, MD ;

Doebber, TW ;

Elbrecht, A ;

Zhang, B ;

Zhou, GC ;

Biswas, C ;

Cullinan, CA ;

Hayes, NS ;

Li, Y ;

Tanen, M ;

Ventre, J ;

Wu, MS ;

Berger, GD ;

Mosley, R ;

Marquis, R ;

Santini, C ;

Sahoo, SP ;

Tolman, RL ;

Smith, RG ;

Moller, DE .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (10) :6718-6725

[4]

Boel Esper, 2000, Current Pharmaceutical Biotechnology, V1, P63, DOI 10.2174/1389201003379004

[5] Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids:: A new class of dual PPARα/γ agonists [J].

Brooks, DA ;

Etgen, GJ ;

Rito, CJ ;

Shuker, AJ ;

Dominianni, SJ ;

Warshawsky, AM ;

Ardecky, R ;

Paterniti, JR ;

Tyhonas, J ;

Karanewsky, DS ;

Kauffman, RF ;

Broderick, CL ;

Oldham, BA ;

Montrose-Rafizadeh, C ;

Winneroski, LL ;

Faul, MM ;

McCarthy, JR .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (13) :2061-2064

[6] A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity [J].

Brown, PJ ;

Winegar, DA ;

Plunket, KD ;

Moore, LB ;

Lewis, MC ;

Wilson, JG ;

Sundseth, SS ;

Koble, CS ;

Wu, ZD ;

Chapman, JM ;

Lehmann, JM ;

Kliewer, SA ;

Willson, TM .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (19) :3785-3788

[7] Identification of a subtype selective human PPARα agonist through parallel-array synthesis [J].

Brown, PJ ;

Stuart, LW ;

Hurley, KP ;

Lewis, MC ;

Winegar, DA ;

Wilson, JG ;

Wilkinson, WO ;

Ittoop, OR ;

Willson, TM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (09) :1225-1227

[8]

CADILLA R, 2002, Patent No. 02062774

[9] A novel potent antagonist of peroxisome proliferator-activated receptor γ blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes [J].

Camp, HS ;

Chaudhry, A ;

Leff, T .

ENDOCRINOLOGY, 2001, 142 (07) :3207-3213

[10]

Cheng PT, 2002, DIABETES, V51, pA94

← 1 2 3 4 5 6 7 8 →